Gamida-Cell  credit: Eyal Izhar Two Elbit Medical exit dreams punctured in a week

InSightec and Gamida-Cell were two great hopes of Israel's biomed industry, but the one faces an uncertain future while Elbit Medical has relinquished the other in a debt settlement.

Gamida Cell  credit: EYal Izhar Gamida Cell to delist as Highbridge takes full ownership

The Israeli stem cell company will lay off 25% of its workforce and close its Jerusalem development center.

Teva CEO Richard Francis credit: Teva Spokesperson FDA rejects Mapi-Viatris long-acting version of Teva's Copaxone

Israeli company Mapi could receive milestone payments from Viatris worth tens of millions of dollars, and royalties from sales, if the product ever reaches the market.

Phage therapy co BiomX merges with APT, raises $50m

The Israeli company's share price jumped 150% on the news.

Healthee team credit: Healthee PR Employer healthcare costs co Healthee raises $32m

The Israeli company has developed a platform to enhance care outcomes and reduce overheads for both employers and employees.

Micha Breakstone  credit: Jonathan Bloom Stem cells meet AI

Together with Harvard and MIT scientists, Micha Breakstone founded, which combines stem cell and AI techniques to develop new therapies.

"Newsweek" lists Israeli hospital in world's best ten

The US magazine has named Sheba Medical Center in Tel Hashomer as the world's ninth best hospital.

start-ups FDA approves X-trodes monitoring patch

The product can measure brain and heart activity and many other physiological signs.

Teva CEO Richard Francis credit: Teva Spokesperson Teva CEO: It's a long way back to being 'share of the nation'

Richard Francis is confident that Teva's share price will continue to rise but says it will take many years to get back to its 2015 peak.

Biotech news credit: Tali Bogdanovsky, Shutterstock Kadimastem plans listing on Nasdaq through merger

The Israeli biotech stem cell company will delist from the TASE.

Brainsway on the rise credit: Tali Bogdanosky New business model transforms Brainsway's fortunes

The company, which has developed and marketings a helmet for deep transcranial magnetic stimulation, has seen its share price rise 230% in the past year.

Teva's R&D labs in Netanya  credit: Teva PR Teva enlarges workforce for first time since 2016

The Israeli pharmaceutical company had 36,472 employees at the end of 2023, up 3.8% from 2022, as it returned to growth.

Vincent Tchenguiz Photo: Christopher Ratcliffe Bladder cancer treatment co Vessi Medical raises $16.5m

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to transurethral resection of bladder tumor.

Naftali Bennett credit: Yediot Ahronot Yoav Dudkevitch Naftali Bennett joins board of Israeli biotech co

Former Israeli Prime Minister Naftali Bennett has joined the board of Remepy, which is pioneering hybrid drugs that include therapeutic applications that enhance the drug effect.

Researchers survey  credit: Gil Gibli Global academic community snubbbing Israeli researchers

A survey finds young Israeli researchers struggling to secure vital international collaboration, and that more wish to leave the country.

Teva  credit: Cineberg/Shutterstock Analysts bullish on Teva

Data from "The Wall Street Journal" show that just three months ago the analysts' consensus on Teva's share price was neutral, whereas today it is positive.

Dr. Ami Appelbaum  credit: Jonathan Bloom Israels former top scientist lashes out

After six years as chair of the Israel Innovation Authority, Dr. Ami Appelbaum champions its independence from political control, and describes his fears and hopes for Israel's tech sector.

Alzheimer's Disease  credit: Shutterstock Insightec device aids Alzheimer's drug delivery - study

A study at the WVU Rockefeller Neuroscience Institute found that Insightec's focused ultrasound device enabled a drug to cross the blood-brain barrier rapidly.

Teva's R&D labs in Netanya  credit: Teva PR The Phoenix becomes party at interest in Teva

At the end of 2023, Israeli insurance and finance group The Phoenix Holdings' stake in Teva was 5.4%.

Richard Francis credit: PR Teva to sell API activity, beats analysts on Q4

The Israeli pharmaceutical company is to divest its active-pharmaceutical ingredient business in the small-molecule industry.

M&A's credit: Shutterstock Healthcare market exudes optimism that excludes Israel

Israel's life sciences and medical devices market has begun 2024 out of step with the international mood because of the war.

Yaky Yanay Photo: Einat Levron Israeli co Pluri launches cell-based coffee

Compared with traditional methods of coffee production, Pluri’s cell-based coffee is estimated to cut water usage by 98%.

Teva  credit: Cineberg/Shutterstock Jefferies raises Teva to "Buy"

The US investment bank has also raised its target price for the Israeli pharmaceutical company's share to $14.

Taro facility in Haifa  credit: PR Taro to become wholly owned by Sun Pharma

India's Sun Pharmaceutical Industries will pay $43 per share for the 21.5% of Taro that it does not already own. Taro employs 1,550 people in Israel.

Aleph Farms beef cuts credit: Aleph Farms Israel approves marketing of Aleph Farms cultured steak

Aleph Farms still has to receive approval for its production line with procedures expected to be completed in the coming months so that the products will be available by mid-2024.

Prof. Ronni Gamzu, Yoav Kish, Prof. Arnon Afek  credit: Yossi Cohen, Marc Israel Sellem (Jerusalem Post), Ouria Tadmor Battle over Israel's new medical school heats up

The Council for Higher Education is due to publish revised conditions for setting up a medical school, behind which is a clash between Reichman University and the existing schools.

Teva  credit: Cineberg/Shutterstock Teva once again most valuable company on TASE

The Israeli pharmaceutical company's share price has risen 50% over the past six months but is still 80% down on its peak in 2015.

Cancer detection credit: Shutterstock Veracyte to buy Israeli cancer detection co C2i Genomics

The US cancer diagnostics company will pay up to $95 million for C2i Genomics, which has raised $112 million.

Teva  credit: Cineberg/Shutterstock Teva ends 2023 as Israeli co with biggest profit on Wall Street

Teva has outshone ICL, Check Point and Mobileye in terms of revenue and profit but not profitability.

Dr. Shimon Eckhouse  credit: Tomer Shalom Sofwave receives two FDA approvals

The Israeli company has received approvals for its devices for improving skin appearance and toning muscles.

Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018